Skip to content
Catalyst

PapersPMID:33437217

Benefits of resistant starch type 2 for patients with end-stage renal disease under maintenance hemodialysis: a systematic review and meta-analysis.

International journal of medical sciences2021The record ↗

findings
2
compound
1
endpoints
2
  1. Finding, moderate evidenceno difference foundSerum uric acid
  2. Finding, moderate evidenceno difference foundSerum albumin
Study, every finding
meta-analysis

No finding here moved its endpoint.

  • “The level of UA did not vary between the RS2 group and the control group (WMD = 0.17, 95% CI: -0.23 to 0.58, I2 = 0%, P = 0.40, Figure 3c).”
    Effect
    0.17 mean difference, 95% CI −0.23 to 0.58
    Population
    Adult patients with end-stage renal disease on maintenance hemodialysis, pooled from randomized trials; primary outcome
  • “We found insignificant changes of albumin in the RS2 group (WMD = 0.06, 95% CI: -0.06 to 0.18, I2 = 0%, P = 0.33, Figure 6a).”
    Effect
    0.06 mean difference, 95% CI −0.06 to 0.18
    Population
    Adult patients with end-stage renal disease on maintenance hemodialysis, pooled from randomized trials; secondary outcome

Study record

Design
meta-analysis
Species
human
Population
Adult patients with end-stage renal disease under maintenance hemodialysis; five RCTs of resistant starch type 2 (RS2, from two Ingredion companies, United States and Australia) given for 4 weeks to 2 months against placebo or control
Participants
179
Comparator
placebo
Duration
not reported
Endpoints measured
9